NCT06862960View on ClinicalTrials.gov

Ozanimod in Patients With Alzheimer's Disease

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

40

Participants

Timeline

Start Date

July 1, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

December 30, 2027

Conditions

Alzheimer Disease

Interventions

DRUG

Ozanimod

A sphingosine-1-phosphate receptor regulator

DRUG

Conventional medication

Conventional medications for moderate AD

All Listed Sponsors

collaborator

Fujian Medical University Union Hospital

OTHER

lead

ChenXiaoChun

OTHER